Media Coverage

07/08/2018

Sienna Announces Exclusive Distribution Partner Appointed for Mainland China

GaoYuan In-Vitro Reagents Co. appointed as exclusive distributor. China is a fast growing consumer of in-vitro diagnostic (IVD) tests. GaoYuan to lead regulatory and approval process with China Food and Drug Administration (CFDA).

 


07/08/2018

Sienna Appoints Exclusive Distribution Partner for mainland China

Sienna announced the appointed Shaanxi GaoYuan In Vitro Diagnostic Reagents Co. (“GaoYuan”) as the Company’s exclusive distribution partner for mainland China.

 


07/08/2018

Sienna Appoints Shaanxi Gaoyuan China Distributor

Sienna says the Xi’an, China-based Shaanxi Gaoyuan In-vitro Diagnostic Reagents Co will distribute its in-vitro adjunct diagnostic for bladder cancer in mainland China.

 


07/08/2018

Sienna Diagnostics Inks Chinese Distribution Deal

Sienna Cancer Diagnostics said today that it has signed on Shaanxi GaoYuan In Vitro Diagnostic Reagents as its exclusive distribution partner in mainland China.

 


18/06/2018

James Mirams, Paradigm Wealth Take 5% Of Sienna

Melbourne’s Paradigm Wealth Management says it has become a substantial shareholder in Sienna with 9,105,829 shares or 5.05 percent.

 


14/06/2018

Investment Administration Services Takes 5% Of Sienna

Investment Administration Services (IAS) says it has become a substantial shareholder in Sienna with 9,105,829 shares or 5.05 percent of the company.

 


14/06/2018

News and Industry Insights

Member News: Johns Hopkins Hospital study of Sienna Cancer Diagnostics IVD test for bladder cancer published.

 


22/05/2018

Sienna Announces R&D Tax Incentive Refund Received

Sienna Cancer Diagnostics Ltd, a medical technology company developing and commercialising innovative cancer-related tests, is pleased to announce the Company has received its R&D Tax Incentive Refund of $631,691 for the 2017 financial year.

 


22/05/2018

Sienna Receives $632k Federal R&D Tax Incentive

Sienna says it has received $631,691 from the Australian Tax Office under the Federal Government Research and Development Tax Incentive program.

 


 

06/04/2018

Mutual Assurance

HR Monthly – Clive Hopkins and Stephanie Wanless

Work Experience: It's a win-win situation. Two SMEs show how much-needed project work has benefitted them and their graduate interns.

Case Study - Sienna Cancer Disgnostics

Education without work experience is kind of like strawberries without cream, or gin without tonic.

 


03/04/2018

How Cycling Helps CEO Matthew Hoskin Come Up With Business Solutions

Interview with Matthew Hoskin for the Life and Leasure section of the Financial Review. Matthew gets in a plug for Sienna and the progress the company has made.

 


13/03/2018

Sienna Cancer Diagnostics Achieves First Sale of Cancer Test in Switzerland

Sienna Cancer Diagnostics Ltd (ASX:SDX) has achieved the first sale of its hTERT cancer test in Switzerland through its distribution partner, Biosystems Switzerland AG.

 


19/02/2018

Sienna Announces StatLab Confident in Growth Trajectory of hTERT Test in USA

StatLab CEO Dan Eckert discusses the US market opportunity for its business, how Sienna’s hTERT product fits into StatLab’s growth strategy, the approach taken by StatLab sales personnel, including hiring the company’s first Advanced Diagnostics Sales Specialist to focus on larger opportunities and increasing industry presence at urology conferences, and the significant interest in the hTERT test shown by pathology laboratories to date.


04-Dec-2017

Sienna Cancer Diagnostics actively seeking acquisitions to drive revenue growth - CEO

Journalist Louise Weihart from the Mergermarket Sydney office: Sienna Cancer Diagnostics [ASX:SDX], an Australian diagnostic technology company, is actively seeking acquisitions to expand its product offering and drive revenue growth, said Chief Executive Officer Matthew Hoskin...



13/11/2017

Johns Hopkins Hospital Study Data to be Presented at USCAP 2018

An abstract discussing the results of a study performed by researchers at The Johns Hopkins Hospital in Baltimore, USA, has been accepted by the United States and Canadian Academy of Pathology (USCAP) for presentation at their annual conference in March 2018. 



08/11/2017

John Hopkins completes Sienna bladder cancer test study

Sienna says that Johns Hopkins Hospital has completed a 500-patient study testing of its telomerase-based in-vitro diagnostic for bladder cancer.

Sienna said that the Baltimore, Maryland-based Johns Hopkins Hospital study investigated the presence of human telomerase reverse transcriptase (hTERT) a cancer-related biomarker in urothelial cells.



08/11/2017

Sienna Announces Johns Hopkins Hospital Study Data to be Presented at USCAP 2018

An abstract discussing the results of a study performed by researchers at Johns Hopkins Hospital in Baltimore, USA, has been accepted by the United States and Canadian Academy of Pathology (USCAP) for presentation at their annual conference in March 2018.


03/11/2017

Tissue Diagnostics Market Worth 5.14 Billion USD by 2022

New market report released by MarketsAndMarkets lists Sienna Cancer Diagnostics amongst key players in the growing diagnostics market. 


October 2017

Connecting Biotech Students with Industry

Sienna, along with others including CSL, Cell Therapies and Trajan, engaged in student projects as part of the Master of Biotechnology program at University of Melbourne.


18/10/2017

Sienna Cancer Diagnostics, Appendix 4C - Quarterly Cash Flow Report

FNN article covering the release of Sienna's 4C for the quarter ending Sept 2017. The cash balance at 30 September was $4.1 million, with net cash inflow for the quarter totalling $3.4 million. New capital issued through the Company’s IPO contributed $4.4 million during the quarter and receipts from product sales were $243,000.
 


27/09/2017

Sienna Cancer Diagnostics (ASX:SDX) talks IVD test sales

In this interview with Jessica Amir from Finance News Network, Sienna CEO Matthew Hoskin highlights FY17 results and speaks to the process that drove strong sales of Sienna’s in vitro diagnostic (IVD) test. Additionally, he covers the Company’s rising position in the US and European Union markets and outlines future product developments for the organization.


26/09/2017

Sienna appoints exclusive distributor for Denmark and Sweden

Article from Ausbiotech's Biotech Dispatch covering Sienna's distribution agreement with Axlab for Denmark and Sweden. 


25/09/2017

Sienna Diagnostics: Exclusive Distributor Appointed for Denmark and Sweden

Article from BioMelbourne Network describing Sienna's new distribution agreemnt with AxLab


25/09/2017

Sienna Appoints Denmark and Sweden Distributor

In this edition of Morgans Daily, a brief update was provided on Sienna’s appointment of Denmark-based Axlab as the exclusive distributor for its adjunct bladder cancer test in Denmark and Sweden.


25/09/2017

Sienna Cancer Diagnostics Announces Exclusive Distributor Appointed for Denmark and Sweden

On Monday 25 September, Sienna announced that it was delighted with the appointment of Axlab A/S as its exclusive distribution partner for Denmark and Sweden. The agreement provides Axlab with the right to sell Sienna’s product to pathology laboratories where it will be used as an adjunct to urine cytology to assist pathologists and urologists in their diagnosis of bladder cancer.


25/09/2017

Sienna Cancer Diagnostics Inks Distribution Agreement with Axlab

On Monday 25 September, Sienna announced that it has entered an agreement that retains Axlab as its exclusive distribution partner for Denmark and Sweden.


25/09/2017

Sienna Cancer Diagnostics to Launch its in-vitro Test in Denmark and Sweden

This article outlines the new distribution agreement in Denmark and Sweden to accelerate the global roll out of Sienna’s hTERT IVD test. Sienna’s test help urologist detect bladder cancer.


25/09/2017

Sienna: Axlab Bladder Test Distributor for Denmark, Sweden

On Monday 25 September, Sienna announced that it was delighted with the appointment of Axlab A/S as its exclusive distribution partner for Denmark and Sweden. This is the first distribution agreement to be signed since Sienna’s ASX listing and will broaden and accelerate the global roll out of its in-vitro diagnostic (IVD) test.


08/09/2017

Daily News on ASX-listed Biotechnology Companies

In this article David Neate, Sienna’s largest shareholder, says he has increased his substantial shareholding in Sienna from 17,002,970 shares (9.43%) to 18,852,970 shares (10.46%). Mr Neate bought 1,850,000 shares on market on August 3 and September 5, 2017 for $296,678 or 16 cents a share.


25/08/2017

Dr Boreham’s Crucible: Sienna Cancer Diagnostics

In this edition of Dr Boreham’s Crucible, Tim Boreham takes a critical look at Sienna’s recent initial public offer while outlining the enormous potential of Sienna’s simple diagnosis tool for pathology labs.


21/08/2017

Sienna Cancer Diagnostics Eyes U.S. for Bladder Cancer IVD following Australian IPO

After raising A$4.6 million through its initial public offering on the Australian Securities Exchange, Sienna Cancer Diagnostics is gearing up to launch the first test to detect telomerase in clinical samples.


31/07/2017

Sienna IPO Raises $4.6m to List on Thursday

Sienna Cancer Diagnostics raised $4.6 million in its initial public offer at 20 cents a share and expects to list on the ASX under the code SDX on Thursday, August 3.


14/07/2017

Sink or Swim podcast: Episode 2 - GetSwift Ltd and Robo 3D Ltd

In this episode of Sink or Swim, OzFinancial CEO Patrick Nelson discusses valuations with Matthew Lindh, Managing Director at Sequoia Corporate Finance. Matthew uses Sienna as an example in his explanation. The Matthew Lindh interview starts at 21:10 into the podcast.

 


30/06/2017

Biotech Company Focused on the Development and Commercialisation of Novel IVD Tests

Australia's Health Professional Radio audio interview with Sienna CEO, Matthew Hoskin in which Sienna's hTERT test is explained to medical professionals.

 

 


20/06/2017

Sienna Cancer Diagnostics not without risk

This article covers Sienna Cancer Diagnostics’ plan to list on the ASX in the following month. Having passed a big hurdle by registering with the US Food & Drug Administration and established distribution partners in the US and Europe, could provide quick access to the Company’s target market.


15/06/2017  

Sienna Develops Early Cancer Detection Test

Sharecafe article talking about the upcoming Sienna IPO and the fact that Sienna is unique among its biotech peers because of existing revenues and regulatory filings.

13/06/2017

 

Sienna Cancer Diagnostics (ASX:SDX) CEO, Matthew Hoskin, discusses its diagnostic technology and upcoming IPO

4-traders article covering Matthew Hoskin's interview with Carolyn Herbert of Finance News Network.

 

 

 


Sign up for updates